Extended Data Fig. 4: Quality Control and Predictive Analyses in Lung Cancer Cell Line Screens.

A) Concordance between Lung Cancer and PRISM Screens: Illustrates the correlation (Rho on x-axis) and significance (y-axis) between our lung cancer screen and PRISM. Focuses on cell lines showing significantly positive correlation, as indicated by Pearson’s r test p-value. B) Predicted vs. Observed Viability Comparison: Analyzes the correlation between predicted and observed cell viability (N = 94 viability observations each, both centered and scaled). Pearson correlation and significance are noted. A best fit line with a 95% confidence interval is shown. C) Viability Prediction in Top vs. Bottom 50% Cell Lines: Compares predicted viability in resistant (N = 11, bottom 50%) versus sensitive (N = 10, top 50%) cell lines for each drug. Uses one-tailed Wilcoxon rank-sum test for statistical significance, presented for each drug. D) Combination Response Prediction in 21 Lung Cancer Cell Lines: Similar to panel B, this compares predicted versus observed combination viability (N = 49 viability observations each), with Pearson correlation and significance provided. A best fit line with a 95% confidence interval is included. E) Combination Viability Prediction in Top vs. Bottom 50% Cell Lines: Analyzes predicted combination viability (centered and scaled) for resistant (N = 11) and sensitive (N = 10) cell lines (based on observed viability) across 7 drug pairs. Uses one-tailed Wilcoxon rank-sum test for significance, presented for each combination. F) Consolidated Analysis of Monotherapies and Combinations: Integrates data from distinct drugs in panel E for combined analysis of monotherapies (N = 188) and drug combinations (N = 98). All box plots show median, 25th/75th percentiles, and range.